Drug Profile
Research programme: islet amyloid polypeptide inhibitors - Innodia
Alternative Names: ID 1567; NC 935Latest Information Update: 09 Mar 2009
Price :
$50
*
At a glance
- Originator Neurochem
- Developer Innodia
- Class
- Mechanism of Action Islet amyloid polypeptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 17 Jul 2008 Innodia has been acquired by BELLUS Health
- 11 Apr 2007 Preclinical development is ongoing
- 25 Nov 2003 Preclinical trials in Type-2 diabetes mellitus in Canada (unspecified route)